BioSante Pharmaceuticals, Inc. (BPAX)

[Just the facts maam]

Based on the Nutsyprofessor's analysis, those in the know realize that BPAX stock should presently be sitting in the $3 -$4 range up from $2.50 range prior to December 14, as the testosterone delivery method of Libigel was successfully proven. This moves the yards stick closer to the end zone.

FYI

It appears the extension trial was always part of the plan. You will notice it was first received November 4th, 2010 and updated October 4, 2011


ClinicalTrials.gov Id: NCT01235754

Study Title: Extension Study to Assess Persistence of Benefit of LibiGel for the Treatment of Hypoactive Sexual Desire Disorder (HSDD)
First Received: November 4, 2010
Last Updated: October 4, 2011

Extension Trial

Vince, I am not a day trader and would not benefit from full subscription, so I can not reply privately. In response to your inquiry, "When is the best time to invest in BPAX?" I do not have a crystal ball. Do your homework, you have to comfortable with what you are purchasing. Research all BPAX's products pipeline and it's diversity. In my honest opinion, the negative press in relation to Libigel and GVAX 2008 Phase III trial have created an opportunity that doesn't come around very often.